Study involving Australian women suggests letrozole reduces the risk of postsurgery recurrence of early breast cancer when compared with tamoxifen

An international clinical trial in which the Australian New Zealand Breast Cancer Trials Group (ANZ BCTG) is making a major contribution, has established that in postmenopausal women with early breast cancer, the drug letrozole offers better post-surgery protection against breast cancer recurrence than does tamoxifen, the current standard of care.

Results from the trial, Breast International Group (BIG) 1-98, which involved the largest number of women from Australia recruited to an international